PolyPid raises $50 mln
PolyPid Ltd said Sept. 4 that it raised $50 million in a Series E-1 round led by existing institutional shareholders and including US-based high-net worth investors. National Securities Corp acted as the placement agent for the financing. PolyPid is a clinical-stage biopharmaceutical company focused on developing and commercializing novel, locally administered therapies.
4 September 2019•3 mins read
